WO2018115871A1 - Composition et procédé de production osseuse - Google Patents

Composition et procédé de production osseuse Download PDF

Info

Publication number
WO2018115871A1
WO2018115871A1 PCT/GB2017/053840 GB2017053840W WO2018115871A1 WO 2018115871 A1 WO2018115871 A1 WO 2018115871A1 GB 2017053840 W GB2017053840 W GB 2017053840W WO 2018115871 A1 WO2018115871 A1 WO 2018115871A1
Authority
WO
WIPO (PCT)
Prior art keywords
extracellular vesicles
cells
osteoblast
osteoblasts
osteoconductive
Prior art date
Application number
PCT/GB2017/053840
Other languages
English (en)
Inventor
Liam GROVE
Sophie Cox
Owen Davies
Richard Williams
Original Assignee
The University Of Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1621716.8A external-priority patent/GB201621716D0/en
Priority claimed from GBGB1704917.2A external-priority patent/GB201704917D0/en
Application filed by The University Of Birmingham filed Critical The University Of Birmingham
Publication of WO2018115871A1 publication Critical patent/WO2018115871A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Definitions

  • the present invention relates to methods and compositions for use in bone production including bone formation, repair or regeneration.
  • Bone fractures represent a growing worldwide medical and socioeconomic burden, with 8.9 million reported annually solely as a result of osteoporosis.
  • bone Despite the natural regenerative capacity of bone, there are instances where healing is impaired and clinical intervention becomes essential. Examples include when the quantity of bone required is simply beyond the body's natural regenerative capacity, such as in the skeletal reconstruction of large defects resulting from trauma or invasive surgeries (e.g. osteosarcoma excision), delayed or non-unions, or when the natural regenerative capacity is impaired due to osteoporosis or avascular necrosis.
  • Standard clinical approaches currently used to stimulate or augment bone regeneration include distraction osteogenesis and bone transport, autologous or allogeneic bone grafts, or the application of bone graft substitutes containing hyper-concentrated growth factors such as bone morphogenetic proteins.
  • autologous grafts are limited by the availability of donor tissue. Allogenic grafts present a potential source of infection and are typically stripped of many osteoinductive biological factors. Materials-based templates often result in the formation of bone that is difficult to remodel and subsequently prone to secondary fracture.
  • Osteoinductive growth factors such as bone morphogenetic proteins (BMPs) have been the subject of recent controversy, with reports of serious negative outcomes and costly litigation. Therefore, although current interventions offer a valuable means to facilitate bone repair, none of these clinical interventions can be considered optimal and potent methods of inducing osteogenesis that are able to generate large volumes of biologically safe and mechanically resilient bone without associated patient morbidity are required.
  • extracellular vesicles in cell-cell and cell-organ communication is becoming increasingly apparent, with these small heterogeneous vehicles delivering a large cargo of proteins, DNA, mRNAs, miRNAs and other important biological molecules between cells. Nowhere is the critical developmental role of extracellular vesicles more apparent than in the skeletal system, where extracellular vesicles have historically been associated with sites of early mineral formation in bone and cartilage.
  • extracellular vesicles as a vehicle for the delivery of bioactive factors that can be utilised for regenerative medicine is only just becoming apparent (Qin et al, 2016, Int. J. Mol. Sci. 17 712).
  • extracellular vesicles are subject to considerably fewer safety considerations, there is no risk of phenotypic conversion or teratogenicity upon implantation, and there are thought to be no immunological issues due to the fact that induced pluripotent stem cell-derived exosomes have previously been shown to lack MHC class I and II proteins.
  • extracellular vesicles it is surprising that only a limited number of studies have sought to utilise these valuable factors for regenerative medicine applications.
  • An aim of the present invention is to provide extracellular vesicles with improved properties, and to provide an improved protocol/method for the administration of extracellular vesicles which results in improved bone production.
  • extracellular vesicles derived from osteoblasts or osteoblast-like cells comprising elevated levels of one or more of an annexin protein, osteopontin and collagen type-VI.
  • the level of both osteopontin and collagen type-VI in the extracellular vesicles are elevated compared to levels observed in extracellular vesicles derived from non-mineralising osteoblasts or osteoblast-like cells.
  • the level of both an annexin protein and collagen type-VI in the extracellular vesicles are elevated compared to levels observed in extracellular vesicles derived from non-mineralising osteoblasts or osteoblast-like cells.
  • the extracellular vesicles are derived from osteoblasts or osteoblast-like cells cultured in a mineralising environment, for example in the presence of an osteoconductive donor substrate .
  • the level of osteopontin observed in extracellular vesicles derived from osteoblasts or osteoblast-like cells cultured in a mineralising environment may be at least 2 fold, at least 3 fold, at least 4 fold or more than that observed in extracellular vesicles derived from osteoblasts or osteoblast-like cells cultured in a non-mineralising environment.
  • the level of collagen type-VI observed in extracellular vesicles derived from osteoblasts or osteoblast-like cells cultured in a mineralising environment may be at least 2 fold, at least 3 fold, at least 4 fold or more than that observed in extracellular vesicles derived from osteoblasts or osteoblast-like cells cultured in a non- mineralising environment.
  • extracellular vesicles derived from osteoblasts or osteoblast-like cells cultured in a mineralising environment have a level of osteopontin at least 4 fold more than that observed in extracellular vesicles derived from osteoblasts or osteoblast-like cells cultured in a non-mineralising environment, and a level of collagen type-VI at least 3 fold more than that observed in extracellular vesicles derived from osteoblasts or osteoblast-like cells cultured in a non-mineralising environment.
  • the annexin protein may be Annexin 2, Annexin 1 or Annexin 6.
  • the level of one or more annexins observed in extracellular vesicles derived from osteoblasts or osteoblast-like cells cultured in a mineralising environment may be at least 2 fold, at least 3 fold, at least 4 fold or more than that observed in extracellular vesicles derived from osteoblasts or osteoblast-like cells cultured in a non-mineralising environment.
  • the level of Annexin 2 observed in extracellular vesicles derived from osteoblasts or osteoblast-like cells cultured in a mineralising environment may be at least 2 fold, at least 3 fold, at least 4 fold or more than that observed in extracellular vesicles derived from osteoblasts or osteoblast-like cells cultured in a non-mineralising environment.
  • Extracellular vesicles derived from osteoblasts or osteoblast-like cells cultured in a mineralising environment may have Annexin 1 and/or Annexin 6 which are otherwise absent from extracellular vesicles derived from osteoblasts or osteoblast-like cells.
  • Osteoblast-like cells include odontoblasts (located within dentine), ameloblasts (located within enamel), cementoblasts (located within cementum) and skeletal muscle cells.
  • the invention provides a composition comprising extracellular vesicles according to the first aspect of the invention.
  • a pharmaceutical composition comprising extracellular vesicles derived from osteoblasts or osteoblast-like cells and a pharmaceutically acceptable carrier.
  • the composition is intended for administration with an osteoconductive donor substrate.
  • the extracellular vesicles may be as described with reference to the first aspect of the invention.
  • composition comprising extracellular vesicles derived from osteoblasts or osteoblast-like cells and an osteoconductive donor substrate.
  • the composition is a pharmaceutical composition and further comprises a pharmaceutically acceptable carrier.
  • the extracellular vesicles may be as described with reference to the first aspect of the invention.
  • a method of promoting bone formation/regeneration in a subject at a site in need thereof comprising the steps of: (i) obtaining extracellular vesicles obtained from osteoblasts or osteoblast- like cells;
  • the extracellular vesicles obtained in step (i) were obtained from osteoblasts cultured in the presence of one or more osteoconductive donor substrate .
  • the extracellular vesicles and osteoconductive donor substrate may be administered sequentially, simultaneously or separately.
  • the extracellular vesicles may be as described with reference to the first aspect of the invention.
  • a method of promoting bone formation/regeneration in vitro comprising the steps of:
  • the extracellular vesicles obtained in step (i) were obtained from osteoblasts or osteoblast-like cells cultured in the presence of one or more osteoconductive donor substrate .
  • the extracellular vesicles and osteoconductive donor substrate may be administered sequentially, simultaneously or separately.
  • the extracellular vesicles may be as described with reference to the first aspect of the invention.
  • the cells may be autologous or heterologous stem cells, osteoblasts or osteoblast-like cells, preferably the stem cells, osteoblasts or osteoblast-like cells are autologous to the subject to whom they will be administered.
  • This method may be used to induce mineralisation in the cells, that is, the early stages of bone formation, prior to administration of the cells to a subject.
  • the cells such as stem cells, osteoblasts or osteoblast-like cells may be seeded on a scaffold comprising an osteoconductive donor substrate, thereby allowing the production of a scaffold primed for bone regeneration before it is administered.
  • the in vitro method described may be used with any standard tissue engineering method/protocol.
  • the invention provides a method of treating a bone condition in a subject in need of bone regeneration, or of promoting bone formation in a subject where needed, comprising locally administering to the subject a therapeutically effective amount of extracellular vesicles derived from osteoblasts or osteoblast-like cells and an osteoconductive donor substrate.
  • the extracellular vesicles and osteoconductive donor substrate may be administered sequentially, simultaneously or separately.
  • the extracellular vesicles and osteoconductive donor substrate may be in the same composition and administered simultaneously, or they may be in separate compositions and may be administered simultaneously, sequentially or separately.
  • the extracellular vesicles may be as described with reference to the first aspect of the invention.
  • the invention provides use of extracellular vesicles derived from osteoblasts or osteoblast-like cells and an osteoconductive donor substrate in the manufacture of a medicament for use in the treatment of a bone condition or in promoting bone growth/regeneration.
  • the extracellular vesicles may be as described with reference to the first aspect of the invention.
  • the invention provides extracellular vesicles derived from osteoblasts or osteoblast-like cells for use in the treatment of a bone condition or in promoting bone growth/regeneration, wherein the extracellular vesicles derived from osteoblasts or osteoblast-like cells are intended to be administered with an osteoconductive donor substrate.
  • the extracellular vesicles and osteoconductive donor substrate may be intended to be administered sequentially, simultaneously or separately.
  • the extracellular vesicles may be as described with reference to the first, or any, aspect of the invention.
  • the invention provides a composition comprising extracellular vesicles derived from osteoblasts or osteoblast-like cells and an osteoconductive donor substrate for use in the treatment of a bone condition or in promoting bone growth/regeneration.
  • the extracellular vesicles may be as described with reference to the first, or any, aspect of the invention.
  • the invention provides a kit comprising extracellular vesicles derived from osteoblasts or osteoblast-like cells and an osteoconductive donor substrate and instructions for administration to a subject to treat a bone condition and/or to aid in bone growth/regeneration.
  • the extracellular vesicles and osteoconductive donor substrate may be provided in the same composition for administration together.
  • the extracellular vesicles and osteoconductive donor substrate may be provided in separate compositions that are mixed prior to administration.
  • the extracellular vesicles and osteoconductive donor substrate may be provided in separate compositions and may be administered separately. If administered separately the extracellular vesicles and osteoconductive donor substrate may be administered within 10 minutes of each other, for example if both are administered in a fluid form.
  • the extracellular vesicles may be administered several hours or even days later, for example by injection into the scaffold.
  • the extracellular vesicles and osteoconductive donor substrate may be intended for local administration.
  • the kit may further comprise a biocomposite, such as a scaffold or cement.
  • the biocomposite may be mixed with the extracellular vesicles and an osteoconductive donor substrate prior to administration.
  • the biocomposite may comprise the osteoconductive donor substrate, in which case it may be mixed with the extracellular vesicles prior to administration or it may be administered and the extracellular vesicles may be administered separately.
  • the extracellular vesicles may be as described with reference to the first aspect of the invention.
  • the invention provides an implantable device, such as a scaffold, cement or fixation device, which carries or contains extracellular vesicles and/or an osteoconductive donor substrate.
  • the implantable device may include orthopaedic and spinal implants, including screws, plates, rods, pins, hooks, anchors, intramedullary devices, pedicle screws, pedicle hooks, spinal fusion cages, prostheses, porous metal implants such as trabecular metal implants and the like.
  • the extracellular vesicles and/or osteoconductive donor substrate may be coated on the surface of, or applied as a surface modification to, an implantable device by conventional means.
  • the implant may be formulated and fabricated such that the extracellular vesicles and/or osteoconductive donor substrate is incorporated into the implant. Means by which this can be accomplished are well known to those of ordinary skill in the art.
  • the extracellular vesicles may be as described with reference to the first aspect of the invention.
  • the extracellular vesicles may be exosomes and/or macrovesicles.
  • the extracellular vesicles may be exosomes.
  • the extracellular vesicles may have a diameter up to about 300nm, up to about 200nm, up to about 150nm, up to about 125nm, or up to about l OOnm.
  • the extracellular vesicles may have a dimeter of between about 30nm and about 200nm.
  • the exosomes may have a diameter of up to about 150nm, up to about 125nm, up to about l OOnm.
  • the exosomes may have a diameter of between about l Onm and about 150nm, between about 20nm and about 150nm, between about 30nm and about 150nm, between about 40nm and about 125nm, between about 50nm and about l OOnm.
  • the osteoconductive donor substrate may be a mineral donating substrate.
  • the donating substrate may comprise calcium, phosphorus, magnesium, sodium, chloride, pyrophosphate, potassium, fluoride, strontium, zinc, chromium, cobalt, copper, manganese, silicon, carbonate or bicarbonate.
  • the mineral is calcium or phosphorus.
  • the mineral donating substrate may be calcium phosphate, hydroxyapatite, calcium deficient hydroxyapatite, tetracalcium phosphate, alpha- tricalcium phosphate, beta-tricalcium phosphate, octacalcium phosphate, calcium pyrophosphate, dicalcium phosphate dihydrate, dicalcium phosphate anhydrous, beta- glycerophosphate, calcium beta-glycerophosphate or sodium beta-glycerophosphate.
  • the extracellular vesicles are administered to a subject in the presence of one or more of beta-glycerophosphate, calcium beta-glycerophosphate or sodium beta-glycerophosphate.
  • the beta-glycerophosphate, calcium beta- glycerophosphate or sodium beta-glycerophosphate may be provided at a concentration of between about O. lmM and about l OOmM beta-glycerophosphate, preferably between about ImM and about l OOmM, preferably between about 5mM and about 50mM, more preferably about l OmM beta-glycerophosphate.
  • the extracellular vesicles may also be administered with ascorbic acid.
  • the ascorbic acid may be included at a concentration of between about ⁇ g/ml and about 20C ⁇ g/ml, preferably about 3C ⁇ g/ml and about 10C ⁇ g/ml, preferably about 5C ⁇ g/ml.
  • extracellular vesicles from sources other than osteoblasts or osteoblast-like cells are removed. This can be achieved by centrifuging solutions to remove unwanted extracellular vesicles prior to the addition of the extracellular vesicles derived from osteoblasts or osteoblast-like cells.
  • the osteoblast cells or osteoblast-like cells from which the extracellular vesicles are derived may be mammalian osteoblast or osteoblast-like cells.
  • the osteoblast or osteoblast-like cells from which the extracellular vesicles are derived may be human osteoblast or osteoblast-like cells.
  • the osteoblast or osteoblast-like cells from which the extracellular vesicles are derived may be mouse osteoblast or osteoblast-like cells.
  • the extracellular vesicles may be obtained from osteoblasts or osteoblast-like cells by stimulating the osteoblasts or osteoblast-like cells to produce vesicles by culturing the osteoblasts or osteoblast-like cells in a growth medium containing an osteoconductive donor substrate - sometimes referred to as a mineralising environment.
  • a growth medium containing an osteoconductive donor substrate - sometimes referred to as a mineralising environment.
  • the extracellular vesicles are produced in the absence of dexamethasone .
  • the extracellular vesicles may be isolated from the growth medium using various techniques known in the art, including filtration, centrifugation, ion-chromatography or concentration.
  • the extracellular vesicles of the invention may be obtained from osteoblasts or osteoblast-like cells cultured in a growth medium containing between O. lmM and about l OOmM beta-glycerophosphate, preferably between about ImM and about l OOmM, preferably between about 5mM and about 50mM, more preferably about l OmM beta-glycerophosphate .
  • the medium may also comprise ascorbic acid.
  • the ascorbic acid may be included at a concentration of between about ⁇ g/ml and about 200 ⁇ g/ml, preferably about 30 ⁇ g/ml and about 100 ⁇ g/ml, preferably about 50 ⁇ g/ml.
  • the invention may provide a method of producing extracellular vesicles.
  • the method may further include the step of recovering and isolating the extracellular vesicles produced.
  • the extracellular vesicles may be recovered or isolated by using differential centrifugation, ultracentrifugation, precipitation, chromatography or sequential filtration.
  • Extracellular vesicles produced by this method may be useful for hard tissue regeneration, for example bone regeneration.
  • the isolated extracellular vesicles may include one or more types of extracellular vesicles.
  • the isolated extracellular vesicles may comprise one, two, three four, five, six, seven, eight, nine, ten or more types of exosomes.
  • the types of extracellular vesicles may be characterised by their compositions, for example, by the nucleic acids and/or proteins contained in the extracellular vesicles.
  • An osteoconductive donor substrate may be administered simultaneously with the extracellular vesicles, in the same composition or in a separate composition.
  • the osteoconductive donor substrate and extracellular vesicles may be administered sequentially, that is the osteoconductive donor substrate may be administered just before or just after administration of the extracellular vesicles.
  • the osteoconductive donor substrate may be administered 10 minutes before or after administration of the extracellular vesicles.
  • the osteoconductive donor substrate may be administered several hours, or even days, before administration of the extracellular vesicles.
  • the osteoconductive donor substrate may form part of a scaffold/cement which may be administered minutes, hours or days before the administration of the extracellular vesicles.
  • the scaffold/cement comprising the osteoconductive donor substrate may be administered during an invasive procedure to a site in need of bone formation/regeneration, the extracellular vesicles may then be administered either during the invasive procedure or later, for example by injection into the scaffold/cement or to the site where bone formation is needed.
  • the extracellular vesicles, and optionally an osteoconductive donor substrate may be administered in combination with one or more of autograft bone, allograft bone, autologous stem cells, allogenic stem cells, autologous growth factors, allogenic growth factors, chemical stimulation methods, electrical stimulation methods, low- intensity pulse ultrasound methods, internal fixation methods, external fixation methods, a bone scaffold and an orthopaedic biocomposite.
  • the extracellular vesicles may be administered with a biocomposite or scaffold which comprises an osteoconductive donor substrate, for example a mineral composite such as a calcium phosphate scaffold or cement.
  • the extracellular vesicles and/or the osteoconductive donor substrate may be admixed with a biocomposite, such as a cement or a scaffold, prior to administration to a subject.
  • the extracellular vesicles and/or osteoconductive donor substrate may also be intended to be administered with one or more further agents, wherein the further agents may be selected from a cytotoxic agent, a cytokine, a growth inhibitory agent, an further bone growth stimulator, a peptide growth factor, an anti-inflammatory agent, a pro-inflammatory agent, an inhibitor of apoptosis, an MMP inhibitor and a bone catabolic antagonist such as a bisphosphonate, a osteoprotegerin or a statin.
  • the further agents may be selected from a cytotoxic agent, a cytokine, a growth inhibitory agent, an further bone growth stimulator, a peptide growth factor, an anti-inflammatory agent, a pro-inflammatory agent, an inhibitor of apoptosis, an MMP inhibitor and a bone catabolic antagonist such as a bisphosphonate, a osteoprotegerin or a statin.
  • the extracellular vesicles may be loaded with externally added therapeutic agents.
  • Suitable therapeutic agents include pro- angiogenic agents such as VEGF, angiopoietin and PDGF; trace elements such as Cr, Si, Zn, Cu, S and bioactive glasses; antibacterial agents such as antibiotics and silver; bone growth stimulators such as BMPs, TGF-beta, PDGF; and microRNAs such as miPv-218, miPv-96, miR- 199b, miR- 133, miR- 135, miR-26, and miR-29.
  • the extracellular vesicles are not loaded with an external therapeutic agent.
  • the extracellular vesicles according to the invention may act as independent sites of mineralisation (independent of cells).
  • the extracellular vesicles may allow the uptake and processing of one or more of calcium, phosphate and magnesium ions required for mineralisation.
  • the subject may be a mammalian animal, in particular a human.
  • the subject may alternatively be a horse, dog, cat or other domestic animal.
  • the present invention may lead to newly formed bone that has improved bone quality, quantity and density, in particular in comparison to compromised bone which may otherwise be produced at a site of injury.
  • the data presented herein uses X-ray fluorescence elemental mapping to show for the first time that there is enhanced calcium deposition within stem cell cultures treated with extracellular vesicles derived from mineralising osteoblasts and administered with an osteoconductive donor substrate. Furthermore, calcium and phosphorus ions are shown to co-localise when extracellular vesicles derived from mineralising osteoblasts are administered to stem cell cultures with an osteoconductive donor. Co-localisation was absent within stem cell cultures treated with BMP-2 (current clinical gold-standard) or extracellular vesicles administered in the absence of an osteoconductive donor substrate .
  • the method or composition of the invention may be used at, or adjacent to, a site in need of the promotion of bone formation/regeneration.
  • This site may be any of a number of areas including bone that is injured, damaged, fractured, eroded, brittle, or defective in some other way that would benefit from the promotion of bone formation/regeneration at that site.
  • the site may be a site of injury, such as a fracture of a bone.
  • the site may be a site of surgical intervention, such as insertion of an implant into a bone.
  • the site may a site of disease, pathology, condition or disorder.
  • the site may be a bone affected by osteoporosis.
  • the method or composition of the invention may be used to promote bone formation/regeneration in a subject afflicted with a bone condition.
  • the bone condition may be selected from bone fracture; osseous defects: delayed unions; nonunions; bone trauma; arthrodesis including spinal arthrodesis, extremity arthrodesis and the like; a bone deficit condition associated with post-traumatic bone surgery, post-prosthetic joint surgery, post-plastic bone surgery, post-dental surgery, bone chemotherapy treatment, congenital bone defect, post-traumatic bone loss, postsurgical bone loss, post infection bone loss, allograft incorporation or bone radiotherapy treatment; and osteoporosis.
  • the method or composition of the invention may be used to promote fusion of two bones or bone fragments.
  • the method or composition of the invention may be used to promote spinal fusion, for example to treat lumbar degenerative disc disease .
  • the composition may be administered via a spinal cage which may be used to provide load bearing support to the vertebrae .
  • the method or composition of the invention may be used in dental applications, for example to promote bone growth around a dental implant.
  • the method or composition of the invention may be used to promote maxillofacial repair/regeneration and/or to enhance dentine production for the treatment of caries.
  • the method or composition of the invention may also be used to promote osteointegration of metallic or polymeric dental implants, including dental implants for crowns (abutment and abutment screws) and dental bridges.
  • the dosage of the extracellular vesicles and an osteoconductive donor substrate administered will depend on the intended application. The determination of the appropriate dosage and route of administration is well within the skill of the ordinary physician.
  • the extracellular vesicles and/or osteoconductive donor substrate may be administered directly to a site where needed, this may be achieved by injection into the site or adjacent to the site, alternatively the extracellular vesicles and/or osteoconductive donor substrate may be administered surgically as a paste, putty, gel or cement, in combination with a scaffold, as part of an implant, in a viscous fluid or a polymeric solution.
  • the extracellular vesicles and/or osteoconductive donor substrate may be administered entrapped in micro-particles, in a semipermeable matrix or in a biodegradable material such as a hydrogel.
  • the extracellular vesicles and/or an osteoconductive donor substrate may be administered in a form that allows immediate release, controlled release, sustained release or extended released.
  • the present invention provides a method and medium for delivering the extracellular vesicles of the invention.
  • the extracellular vesicles of the invention may be delivered by suspending them in a liquid phase containing polymer fluid gel microparticles as described with reference to cells is WO2014/140549. In an embodiment the extracellular vesicles are not embedded within the microparticles.
  • the rheological properties of the fluid gels "liquid phases" can be controlled to allow these systems to have a range of flow functionalities when applied at a desired location where they should be retained. Properties of the fluid gels can be tailored to each specific application (to be injectable, spreadable, shear-thinning, Newtonian, etc) by controlling the formulation and processing parameters involved during their manufacture .
  • a fluid gel structure can be designed to revert to a typical (non-sheared) gel structure as a function of time, external stimuli (temperature, ionic charge, etc .) .
  • This can allow for the formulation of a fluid gel structure carrying extracellular vesicles that is initially injectable but subsequently, e.g. after application at the point of injury, forms a structure that is firmly anchored but has been shaped to occupy the available space in the body (e.g. not causing any disruption to movement) and still retains the extracellular vesicles.
  • the actual flow behaviour of the fluid gels can be designed to be transient. This can allow for specific flow characteristics (e.g. a high yield stress, etc.) initially exhibited by the system to be either irreversibly or reversibiy altered following application; for example, in the case of a system exhibiting a high yield stress, this behaviour can be temporarily eliminated by the application of shear (while it is injected) during application, but once shear is removed the yield stress functionality returns after a certain (and again controllable) "resting period" .
  • specific flow characteristics e.g. a high yield stress, etc.
  • the invention provides, an extracellular vesicles delivery medium comprising a liquid phase, wherein the liquid phase comprises (i) extracellular vesicles suspended (or entrapped) within the liquid phase and (ii) a plurality of polymer gel particles.
  • the extracellular vesicles are not entrapped within the polymer gel particles but are within the liquid phase. Extracellular vesicles within both the liquid phase and the gel particles may also be provided.
  • a further aspect of the invention provides an extracellular vesicles delivery medium comprising an osieoconductive donor substrate, extracellular vesicles and a plurality of polymer gel particles, wherein said polymer gel particles do not encapsulate the extracellular vesicles.
  • the liquid phase may be any suitable liquid, especially aqueous liquid, for suspending extracellular vesicles.
  • the liquid phase comprises an osieoconductive donor substrate.
  • the polymer gel may be selected from agarose, agar, carrageenan, gellan gum, gelatin, pectin, alginate and fibrin .
  • Non-naturally occurring gels for example, polyacrylate and polyethylene glycol, may be used.
  • Other suitable gels include chitosan, dextran, collagen and hyaluronic acid.
  • the particles may be substantially spherical, needle or threadlike . The particles may be within substantially a single size distribution family or within several discrete size distribution features.
  • the polymer gel may be a hydrogel .
  • Hydrogels typically are networks of polymer chains that are hydrophilic, and are sometimes found as gel in which water is the dispersion medium .
  • examples of hydrogels include gelatin, poly(alkylene oxides) such as poly(ethylene oxide), poiy(meth)acryiates and methyl cellulose.
  • the hydrogel comprises a gellan , a generally known polysaccharide gum which is produced by Pseudomonas elodea. Gellan may be used at 0.5% -3% t/vol of the formulation prior to setting, for example 1 -2.5% wt/vol or 2% wt/vol.
  • Alginate may also be used.
  • gellan and alginate may be used, for example at 0.5%-l% gellan to 0.25- 0.75% alginate.
  • Gellan gum is based on a linear structure of repeating glucose rhamnose and glucuronic acid units.
  • high acyl gum two acyl side chains of acetate and glycerate are present. Both substituents are present on the same glucose molecule and on average there is one glycerate per repeating unit and one acetate every two repeating units.
  • low acyl gellan gums the acyl groups are removed. High acyl products tend to form soft elastic gels while gellan gum produces firmer, less elastic gels.
  • the gellan gum may be high or low acyl or a combination thereof.
  • the average size of the polymer gel particles is 1 to ⁇ ⁇ , ⁇ ⁇ to 500 ⁇ or ⁇ ⁇ to ⁇ ⁇ , or 30 ⁇ to 50 ⁇ .
  • the extracellular vesicles delivery medium may utilise in the polymer gel and/or liquid phase, one or more additional agents such as antibiotics, hormones, growth factors or anti-inflammatory compounds.
  • a further aspect of the invention provides an extracellular vesicles delivery maxim m according to the invention for use in the treatment of a bone condition.
  • the bone condition may be selected from bone fracture; osseous defects: delayed unions; nonunions; bone trauma; arthrodesis including spinal arthrodesis, extremity arthrodesis and the like; a bone deficit condition associated with post-traumatic bone surgery, post-prosthetic joint surgery, post-plastic bone surgery, post-dental surgery, bone chemotherapy treatment, congenital bone defect, post-traumatic bone loss, postsurgical bone loss, post infection bone loss, allograft incorporation or bone radiotherapy treatment; and osteoporosis.
  • the bone condition may be a dental condition as previously described.
  • the extracellular vesicles delivery medium of the invention may be used to promote fusion of two bones or bone fragments.
  • the method or composition of the invention may be used to promote spinal fusion, for example to treat lumbar degenerative disc disease.
  • the composition may be administered via a spinal cage which may be used to provide load bearing support to the vertebrae .
  • the invention also provides methods of treatment using the extracellular vesicles delivery medium according to the invention.
  • a further aspect of the invention provides a method of producing an extracellular vesicles delivery medium comprising:
  • the invention also provides a method of producing an extracellular vesicles suspension medium comprising:
  • Extracellular vesicles may be provided in one or both of the liquid phase and particulates.
  • the mixture comprising the plurality of polymer gel microparticles may be sterilised by irradiation, typically prior to addition of the extracellular vesicles. Irradiation may utilise, for example, ultraviolet, x-ray or gamma ray radiation to sterilise the medium , for example, to remove unwanted bacterial contamination .
  • the shearing is induced by passing the heated mixture through a pin stirrer as it is cooled.
  • the media may be passed through a water bar to cool the extracellular vesicles that are not encapsulated within a polymer gel matrix, but are suspended within the liquid phase of a fluid gel system and surrounded by individual fluid gel microparticles, fluid gels with advantageous properties can be produced.
  • the extracellular vesicles can be mobile within a flowable, spreadable or injectable solution depending on the processing characteristics of the fluid gel component.
  • the properties of the fluid gels can be tailored for each specific application by controlling the formulation and processing parameters involved during the manufacture. This means that there is the ability to specifically design the functionality of the extracellular vesicles carrying system for use in different scenarios and applications.
  • Figure 1 shows the profiling and characterisation of exosomes isolated from osteoblasts cultured in a mineralising environment.
  • Figure la shows topographic profiling of exosomes using AFM under tapping mode .
  • Figure lb shows tunable resistive pulse sensing measurement of exosome size using Izon qNano.
  • Figure l c shows ImageStream detection of lipid membrane (FM 1 - 43FX) and transmembrane surface protein (CD9).
  • Figure 2 shows the osteoinductive effects of exosomes administered according to the invention.
  • Figure 2a shows alkaline phosphatase (ALP) analysis at days
  • Figure 2b shows Alizarin red calcium staining in hMSC cultures exposed to exosomes.
  • Figure 3 illustrates micro-XRF mapping of calcium and phosphorus in hMSC cultures treated with exosomes according to the invention and as depicted in Figure 1.
  • Figure 4 shows upregulation of the expression of type-VI collagen (Col6al , Col6a2 and Col6a3) and osteopontin (Spp l) in exosomes derived from mineralising osteoblasts when compared with exosomes derived from non- mineralising osteoblasts.
  • FIG. 5 shows that extracellular vesicles of the invention can act as independent sites of mineralisation.
  • Transmission electron microscopy with accompanying energy dispersive x-ray spectroscopy (EDX) demonstrates localisation of elements critical in mineralisation to extracellular vesicles.
  • EDX energy dispersive x-ray spectroscopy
  • Figure 6 - is a schematic highlighting the main stages in the manufacture and isolation of pro-osteogenic extracellular vesicles and the two alginate delivery systems developed for local delivery.
  • Figure 6A shows alginate fluid gels notably with a cross-linked gel phase and a continuous alginate phase which is not cross-linked;
  • Figure 6B shows alginate micro-particles produced by vibrating nozzle technology.
  • Figure 7 illustrations the formulation and rheological characterisation of an alginate fluid gel.
  • Figure 7 A shows a range of fluid gel parameters used for fluid gel formulations
  • Figures 7B and C show the influence of agitator speed on shear thinning behaviour
  • Figures 7D and E show the influence of agitator speed on the frequency dependent response of fluid gels
  • Figure 7F shows the influence of the calcium chloride to alginate ratio on force required to inject fluid gels
  • Figure 8 - depicts a homogeneous distribution of extracellular vesicles loaded within a) alginate microparticles (left), and b) alginate fluid gel (right).
  • Extracellular vesicles were labelled with FM 1 -43FX lipid dye to allow for visualisation using a confocal microscopy. 3D images were produced by stacking 2D images.
  • Figure 9 - shows the co-localisation of SYTO ENA select dye (staining extracellular vesicle RNA content) and FM 1 -43FX lipid dye (staining phospholipid EV membrane).
  • Figure 10 - shows the release of extracellular vesicles from alginate microparticles and fluid gel systems
  • hMSCs Human bone marrow-derived human mesenchymal stem cells
  • hMSCs Human bone marrow-derived human mesenchymal stem cells
  • hMSCs were extracted and purified from a young Caucasian male (Lonza, h tip : // w w w. lonza.com).
  • hMSCs were fully profiled for the expression of CD29, CD44, CD 105 and CD 166 and lack of CD 14, CD34, CD45 expression.
  • MC3T3-E 1 murine osteoblasts were purchased from America Type Culture Collection (ATCC, http://www.atcc.org) .
  • Cell culture medium comprised of minimal essential medium (a-MEM) supplemented with 10% foetal bovine serum (FBS), L-glutamine (Sigma) and 1 % penicillin/streptomycin (Sigma).
  • hMSCs were used between passage 4-5. Osteogenic medium was formulated through the addition of l OmM ⁇ -glycerophosphate (Sigma) and 5C ⁇ g/mL L-ascorbic acid (Sigma) . Culture medium used for exosome isolation was depleted of any contaminating exosomes by ultra-centrifuging the FBS at 120,000g for 70 minutes prior to use.
  • MC3T3-E 1 osteoblasts were cultured at scale in T175 culture flasks and the medium isolated every two days for extracellular vesicle isolation. Osteoblasts were grown in either standard culture medium or osteogenic medium for a total period of 14 days. Osteoblast-derived exosomes were isolated by differential centrifugation: 2000g for 20 minutes to remove cell debris and apoptotic bodies, 10,000g for 30 minutes to remove micro-vesicles, 120,000g for 70 minutes to pellet exosomes. Following the final ultracentrifugation step, the supernatant was removed, the pellet washed in sterile phosphate buffered saline (PBS) and further centrifuged at 120,000g.
  • PBS sterile phosphate buffered saline
  • the resulting pellet was re-suspended in 200 of PBS and the total protein concentration determined using a Pierce BCA protein assay kit (Thermofisher Scientific, http://www.thefmofisher.com). Particle size distribution was analysed using Dynamic Light Scattering (DLS, Malvern Instruments) and quantitated using resistive pulse sensing (IZON qNano).
  • DLS Dynamic Light Scattering
  • IZON qNano resistive pulse sensing
  • Nonspecific binding sites were blocked by incubating with 200mM glycine for a period of 30 minutes, and subsequently washed.
  • Secondary fluorescent antibodies, CD9- and CD63 were added to exosome-conjugated beads and incubated at room temperature for 40 minutes with gentle agitation. Fluorescently labelled exosomes were washed, resuspended in PBS and analysed using an FACS Aria I flow cytometry (BD Bioscience). Quantitative Real Time Polymerase Chain Reaction
  • PCR data were normalised to the reference gene ribosomal protein IIB (RPIIB).
  • Relative gene expression levels were calculated from the cycle threshold (C t ) value using the comparative Ct equation ( AA C t ) where relative gene expression is calculated as 2 ⁇ .
  • Alkaline Phosphatase Assay Cellular ALP levels were quantified using the SensoLyte® pNPP Alkaline Phosphatase Assay Kit according to the manufacturer's instructions. Briefly, cell monolayers were washed twice using lx assay buffer provided.
  • Cells were detached from the surface of the culture plate in the presence of 200 ⁇ permeabilisation buffer using a cell scraper. The resulting cell suspension was collected in a microcentrifuge tube, incubated at 4°C for 10 minutes under agitation, and then centrifuged at 2500g for 10 minutes. Supernatant was transferred to a 96 well plate where it was combined with an equal volume of pNPP substrate. Absorbance was measured at 405nm using a plate reader.
  • alizarin red (Sigma) stain, which was dissolved in acetic acid and adjusted to pH 4.2 using 5M ammonium hydroxide. Bound alizarin red was quantified through acetic acid extraction and colorimetric detection at 405nm (GloMax Multi Plus, Promega, UK).
  • Samples for analysis were prepared by transferring mineralised cell monolayers onto an aluminium foil covered glass slide and leaving to dry overnight at room temperature.
  • Maps of calcium and phosphorous across dried cell culture media spot samples were acquired using a Tornado M4 micro-XRF system (Bruker Nano Gmbh, Berlin, Germany) fitted with a Rhodium micro focus X-ray tube and a polycapillary lens, with the X-ray tube voltage set to 50 kV and the tube current set to 300 ⁇ .
  • the chamber pressure was lowered to 20 mbar in order to maximise sensitivity to the phosphorus signal.
  • the system was programmed to acquire a map of the whole slide containing all of the media spot samples by rastering the microfocus beam over the slide with a step size of 30 ⁇ and a time per pixel of 30 ms.
  • An XRF spectrum was collected at each pixel and elemental maps generated progressively in real time by gating around the phosphorous K ai (2.0137 keV) and calcium K ai (3.692 keV) X-ray fluorescence peaks in the spectra, creating an image where pixel intensity represented X-ray detector pulses per eV at each measurement point on the sample. Maximum pixel intensity for each element was normalised to the peak pulses/eV value for that element across the whole sample.
  • RESULTS AND DISCUSSION MC3T3 murine osteoblasts were cultured in the presence of ⁇ -glycerophosphate (osteoconductive donor substrate) according to the methods described herein and extracellular vesicles (EVs), in particular exosomes, were shown to be routinely produced ( Figure 1).
  • Atomic force microscopy ( Figure la) and nanoparticle analysis ( Figure lb) show that EVs with an average size of 150nm are produced by osteoblasts when cultured in osteogenic medium. The EVs were characterised in line with published guidelines (Lotvall J.
  • the data presented in Figure 2 demonstrates that addition of exosomes to human bone marrow-derived stem cell cultures (MSCs) in the presence of an osteoconductive donor substrate significantly enhances the yield and quality of bone formation.
  • the results presented show that the yield and quality of bone formation is well beyond that of the current gold standard, BMP-2.
  • the isolated EVs 10 ⁇ g/mL EVs were added to MSC cultures in the presence of an exogenous phosphate-donating substrate, beta- glycerophosphate, (EV OST - Figure 2) and mineralisation was induced in the MSC cultures.
  • Proteomic analysis showed more than a four-fold increase in osteopontin and more than a three-fold increase in collagen type-VI (alpha- 1 , -2, and -3 chains) in EVs isolated from mineralising osteoblast cultures when compared with EVs from non- mineralising osteoblasts (Figure 4).
  • Osteopontin is recognised as a key regulator of mineralisation and collagen type-VI functions in mediating osteoblast interactions during bone formation. The authors anticipate that increases in these proteins are, in part, responsible for their osteogenesis-enhancing effects.
  • extracellular vesicles can be used for the delivery of mineralising elements to enhance bone formation.
  • the figure demonstrates that when administered in the absence of cells the extracellular vesicles act as independent sites for the delivery and uptake of elements critical for mineralisation. As such, they can be used as an acellular source for enhancing bone regeneration. Delivery of extracellular vesicles
  • Fluid gel compositions with high similarity to the control were chosen for extracellular vesicles encapsulation.
  • the encapsulation process was carried out by suspending extracellular vesicles (6xl 0 9 particles /mL) in alginate solution prior to crosslinking.
  • Alginate microparticles were prepared by suspending extracellular vesicles at the concentration of 6xl 0 9 particles /mL in sterile l %w/v alginate solution ( 1 mL).
  • the microparticles were generated using an encapsulator with the vibrational nozzle technology (A B-395 pro, Buchi, UK) under sterile condition.
  • the generated droplets were incubated in a crosslinking solution (0. 1 M CaCl 2 ) located at 20 cm from the nozzle head for 10 min.
  • the generated microparticles were then subjected to several washes with PBS to remove any remaining unbound calcium ions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des vésicules extracellulaires dérivées d'ostéoblastes ou de cellules de type ostéoblastes, et en particulier leur utilisation dans la promotion de la croissance et de la réparation osseuses.
PCT/GB2017/053840 2016-12-20 2017-12-20 Composition et procédé de production osseuse WO2018115871A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1621716.8A GB201621716D0 (en) 2016-12-20 2016-12-20 Composition and method for bone regeneration
GB1621716.8 2016-12-20
GBGB1704917.2A GB201704917D0 (en) 2017-03-28 2017-03-28 Composition and method for bone production
GB1704917.2 2017-03-28

Publications (1)

Publication Number Publication Date
WO2018115871A1 true WO2018115871A1 (fr) 2018-06-28

Family

ID=60888538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2017/053840 WO2018115871A1 (fr) 2016-12-20 2017-12-20 Composition et procédé de production osseuse

Country Status (1)

Country Link
WO (1) WO2018115871A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020069033A1 (fr) * 2018-09-25 2020-04-02 Oregon Health & Science University Minéralisation de matrices chargées de cellules
CN115957378A (zh) * 2023-02-08 2023-04-14 上海交通大学医学院附属瑞金医院 一种骨修复组合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169202A1 (fr) * 2012-05-10 2013-11-14 Biomatcell Ab Différenciation ostéogénique de cellules souches mésenchymateuses
WO2016201154A1 (fr) * 2015-06-09 2016-12-15 Orthocyte Corporation Unité de formage de greffe ostéogénique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169202A1 (fr) * 2012-05-10 2013-11-14 Biomatcell Ab Différenciation ostéogénique de cellules souches mésenchymateuses
WO2016201154A1 (fr) * 2015-06-09 2016-12-15 Orthocyte Corporation Unité de formage de greffe ostéogénique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALFORD A I ET AL: "Thrombospondin-2 regulates matrix mineralization in MC3T3-E1 pre-osteoblasts", BONE, PERGAMON PRESS., OXFORD, GB, vol. 46, no. 2, 1 February 2010 (2010-02-01), pages 464 - 471, XP026864595, ISSN: 8756-3282, [retrieved on 20090908] *
ANNA CMOCH ET AL: "Matrix vesicles isolated from mineralization-competent Saos-2 cells are selectively enriched with annexins and S100 proteins", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 412, no. 4, 2011, pages 683 - 687, XP028439129, ISSN: 0006-291X, [retrieved on 20110816], DOI: 10.1016/J.BBRC.2011.08.025 *
CYRIL THOUVEREY ET AL: "Proteomic characterization of biogenesis and functions of matrix vesicles released from mineralizing human osteoblast-like cells", JOURNAL OF PROTEOMICS, ELSEVIER, AMSTERDAM, NL, vol. 74, no. 7, 8 April 2011 (2011-04-08), pages 1123 - 1134, XP028387682, ISSN: 1874-3919, [retrieved on 20110415], DOI: 10.1016/J.JPROT.2011.04.005 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020069033A1 (fr) * 2018-09-25 2020-04-02 Oregon Health & Science University Minéralisation de matrices chargées de cellules
CN115957378A (zh) * 2023-02-08 2023-04-14 上海交通大学医学院附属瑞金医院 一种骨修复组合物及其制备方法和应用

Similar Documents

Publication Publication Date Title
Zheng et al. Immunomodulatory bioactive glasses for tissue regeneration
Ren et al. Cerium oxide nanoparticles loaded nanofibrous membranes promote bone regeneration for periodontal tissue engineering
JP5408578B2 (ja) 歯髄幹細胞を用いた自家又は同種移植用組成物及びその用途
Gutwald et al. Mesenchymal stem cells and inorganic bovine bone mineral in sinus augmentation: comparison with augmentation by autologous bone in adult sheep
JP4982841B2 (ja) 再生医療骨組成物
Ignjatović et al. Multifunctional hydroxyapatite and poly (D, L-lactide-co-glycolide) nanoparticles for the local delivery of cholecalciferol
Zhang et al. Effects of compatibility of deproteinized antler cancellous bone with various bioactive factors on their osteogenic potential
Frasca et al. Calcium-phosphate ceramics and polysaccharide-based hydrogel scaffolds combined with mesenchymal stem cell differently support bone repair in rats
Guo et al. Advanced Hydrogel systems for mandibular reconstruction
Wang et al. Hybrid composites of mesenchymal stem cell sheets, hydroxyapatite, and platelet‑rich fibrin granules for bone regeneration in a rabbit calvarial critical‑size defect model
JP2006346420A (ja) 移植材料及び骨質改善剤
CN108283729B (zh) 具有可控镁离子释放行为的可注射骨修复材料及其制备方法
US9220754B2 (en) Keratin compositions for treatment of bone deficiency or injury
Kovács et al. Comparative study of β-tricalcium phosphate mixed with platelet-rich plasma versus β-tricalcium phosphate, a bone substitute material in dentistry
Gutiérrez-Quintero et al. Critical-sized mandibular defect reconstruction using human dental pulp stem cells in a xenograft model-clinical, radiological, and histological evaluation
Chen et al. Dual-function injectable fibrin gel incorporated with sulfated chitosan nanoparticles for rhBMP-2-induced bone regeneration
Wang et al. Construction of vascularized tissue engineered bone with nHA-Coated BCP bioceramics loaded with peripheral blood-derived MSC and EPC to repair large segmental femoral bone defect
El-Kady et al. In-vitro and in-vivo evaluation for the bio-natural Alginate/nano-Hydroxyapatite (Alg/n-HA) injectable hydrogel for critical size bone substitution
WO2018115871A1 (fr) Composition et procédé de production osseuse
Wu et al. Extracellular derivatives for bone metabolism
KR20150058203A (ko) 알긴산염 코팅된 이산화티타늄 스캐폴드의 제조 방법
De Paula et al. Hydroxyapatite-alginate biocomposite promotes bone mineralization in different length scales in vivo
Sawant et al. Bone scaffolds: What's new in nanoparticle drug delivery research?
Sharma¹ et al. Modern approaches to use bioactive materials and molecules in medical and dental treatments
Yagami et al. Honeycomb form β-tricalcium phosphate induces osteogenesis by geometrical property with BMSC

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17822749

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17822749

Country of ref document: EP

Kind code of ref document: A1